Wolfe starts Grail at Peer Perform on time and money needs

As previously reported, Wolfe Research analyst Doug Schenkel initiated coverage of Grail (GRAL) with a Peer Perform rating and no price target Grail is the “pioneer” in multi-cancer early detection, or MCED, through blood-based screening, which is “an exciting and large opportunity, if it works.” Working requires a lot of money and a lot of time, says the firm, which adds “we still aren’t sure GRAL has enough of either,” even before talking about specs, regulatory, and reimbursement.